All In Biotech

Investigational drug · Phase 3

Rilvegostomig

Also called: AZD2936

Not approved by FDA. In 25 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

25

25 still active

All registered trials

37

Any phase or sponsor naming "Rilvegostomig"

First trial start

2020

Jun 3, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Rilvegostomig", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Biliary Tract Cancer
  • Gastric Cancer
  • Non-small Cell Lung Cancer
  • Endometrial Cancer
  • Ovarian Cancer
  • Non-Small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Melanoma
  • Squamous Cell Carcinoma (Skin)

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Ovarian cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Gastroenterology and liver · Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "Rilvegostomig" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 7 on PubMed

Also in development for Biliary Tract Cancer

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • ZimberelimabAB122, GS-0122Phase 312 trials

    Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • TQB2102Phase 311 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors

  • AZD0901Sonesitatug vedotin, CMG901Phase 36 trials

    AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma

  • Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

  • SHR-A1904Phase 35 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Advanced Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.